ALK: We have to reach out to doctors now
ALK failed to hit the primary end-point in a major pediatric study, which nevertheless yielded other positive results, and the allergy drug developer now aims to reach the scientific community with the new knowledge generated. The authorities will have to wait until later, says ALK's chief scientist.
BY LOUISE WENDT JENSEN
Even if you don’t quite reach the finish line, you can still be pleased with the results, says Henrik Jacobi, Chief Science Officer of ALK, after the allergy drug developer published results from a five-year long pediatric study testing the effect of the group’s grass pollen allergy pill Grazax on 812 children aged 5-12.
Allerede abonnent?Log ind her
Læs hele artiklen
Få adgang i 14 dage for 0 kr. Det kræver intet kreditkort, og du vil ikke overgå til et betalt abonnement efterfølgende.
Med din prøveperiode får du:
Få fuld adgang til dig og dine kollegaer
Start et gratis virksomhedsprøveabonnementRelaterede artikler
Analyst: ALK can look forward to long-term sales boost
For abonnenter
ALK reaches a new Japanese milestone
For abonnenter
ALK CEO eyes higher growth rates - in 2017
For abonnenter
